Cancer Anorexia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major cancer anorexia markets are expected to exhibit a CAGR of 10.48% during 2024-2034.
The cancer anorexia market has been comprehensively analyzed in IMARC's new report titled "Cancer Anorexia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Cancer anorexia, also known as cancer-related anorexia-cachexia syndrome, refers to a complex and multifactorial condition characterized by a significant loss of appetite and unintended weight loss in individuals suffering from cancer. The ailment can adversely impact the quality of life and overall well-being of cancer patients, leading to increased morbidity as well as reduced tolerance to cancer treatments. Individuals suffering from the condition may have a decreased desire to eat, an aversion to certain foods, early satiety, and a significant decline in food intake. Various other symptoms may include malnutrition, altered taste perception, fatigue, weakness, etc. Diagnosing cancer anorexia involves a comprehensive investigation by healthcare professionals, typically oncologists, dietitians, and palliative care specialists. The diagnosis is based on clinical evaluation, including the patient's medical history, physical examination, and assessment of symptoms related to appetite loss and unintended weight loss. Several laboratory tests, such as blood work and nutritional markers, may be conducted to assess nutritional status as well as identify any underlying medical conditions contributing to anorexia. Additionally, questionnaires and interviews may be utilized to determine the patient's appetite, dietary intake, and emotional well-being.
The rising cases of tumor formation, which can produce substances that alter the body's metabolism, increase energy expenditure, and lead to appetite suppression, are primarily driving the cancer anorexia market. Besides this, the escalating utilization of cancer treatments, like chemotherapy and radiation therapy, that can have direct effects on the gastrointestinal tract, causing nausea, vomiting, and altered taste perception, thereby reducing food intake, is creating a positive outlook for the market. Moreover, the widespread adoption of appetite stimulants for increasing appetite, supporting weight maintenance, and improving overall nutritional status is further bolstering the market growth. Apart from this, the inflating application of novel taste alteration therapies, such as zinc supplementation and taste-modifying agents, since they aim to restore the sense of taste and enhance food intake in cancer patients, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of probiotics, prebiotics, and fecal microbiota transplantation to reinstate gut microbial balance, reduce inflammation, and improve nutrient absorption, thus potentially alleviating anorexia-related symptoms, is expected to drive the cancer anorexia market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the cancer anorexia market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for cancer anorexia and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the cancer anorexia market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the cancer anorexia market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the cancer anorexia market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current cancer anorexia marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Key Questions Answered in this Report:
Market Insights
How has the cancer anorexia market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the cancer anorexia market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the cancer anorexia market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of cancer anorexia across the seven major markets?
What is the number of prevalent cases (2018-2034) of cancer anorexia by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of cancer anorexia by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with cancer anorexia across the seven major markets?
What is the size of the cancer anorexia patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of cancer anorexia?
What will be the growth rate of patients across the seven major markets?
Cancer Anorexia: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for cancer anorexia drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the cancer anorexia market?
What are the key regulatory events related to the cancer anorexia market?
What is the structure of clinical trial landscape by status related to the cancer anorexia market?
What is the structure of clinical trial landscape by phase related to the cancer anorexia market?
What is the structure of clinical trial landscape by route of administration related to the cancer anorexia market?
The cancer anorexia market has been comprehensively analyzed in IMARC's new report titled "Cancer Anorexia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Cancer anorexia, also known as cancer-related anorexia-cachexia syndrome, refers to a complex and multifactorial condition characterized by a significant loss of appetite and unintended weight loss in individuals suffering from cancer. The ailment can adversely impact the quality of life and overall well-being of cancer patients, leading to increased morbidity as well as reduced tolerance to cancer treatments. Individuals suffering from the condition may have a decreased desire to eat, an aversion to certain foods, early satiety, and a significant decline in food intake. Various other symptoms may include malnutrition, altered taste perception, fatigue, weakness, etc. Diagnosing cancer anorexia involves a comprehensive investigation by healthcare professionals, typically oncologists, dietitians, and palliative care specialists. The diagnosis is based on clinical evaluation, including the patient's medical history, physical examination, and assessment of symptoms related to appetite loss and unintended weight loss. Several laboratory tests, such as blood work and nutritional markers, may be conducted to assess nutritional status as well as identify any underlying medical conditions contributing to anorexia. Additionally, questionnaires and interviews may be utilized to determine the patient's appetite, dietary intake, and emotional well-being.
The rising cases of tumor formation, which can produce substances that alter the body's metabolism, increase energy expenditure, and lead to appetite suppression, are primarily driving the cancer anorexia market. Besides this, the escalating utilization of cancer treatments, like chemotherapy and radiation therapy, that can have direct effects on the gastrointestinal tract, causing nausea, vomiting, and altered taste perception, thereby reducing food intake, is creating a positive outlook for the market. Moreover, the widespread adoption of appetite stimulants for increasing appetite, supporting weight maintenance, and improving overall nutritional status is further bolstering the market growth. Apart from this, the inflating application of novel taste alteration therapies, such as zinc supplementation and taste-modifying agents, since they aim to restore the sense of taste and enhance food intake in cancer patients, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of probiotics, prebiotics, and fecal microbiota transplantation to reinstate gut microbial balance, reduce inflammation, and improve nutrient absorption, thus potentially alleviating anorexia-related symptoms, is expected to drive the cancer anorexia market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the cancer anorexia market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for cancer anorexia and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the cancer anorexia market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the cancer anorexia market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the cancer anorexia market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current cancer anorexia marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Key Questions Answered in this Report:
Market Insights
How has the cancer anorexia market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the cancer anorexia market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the cancer anorexia market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of cancer anorexia across the seven major markets?
What is the number of prevalent cases (2018-2034) of cancer anorexia by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of cancer anorexia by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with cancer anorexia across the seven major markets?
What is the size of the cancer anorexia patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of cancer anorexia?
What will be the growth rate of patients across the seven major markets?
Cancer Anorexia: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for cancer anorexia drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the cancer anorexia market?
What are the key regulatory events related to the cancer anorexia market?
What is the structure of clinical trial landscape by status related to the cancer anorexia market?
What is the structure of clinical trial landscape by phase related to the cancer anorexia market?
What is the structure of clinical trial landscape by route of administration related to the cancer anorexia market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 CANCER ANOREXIA - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 CANCER ANOREXIA - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 CANCER ANOREXIA - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 CANCER ANOREXIA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 CANCER ANOREXIA - UNMET NEEDS
10 CANCER ANOREXIA - KEY ENDPOINTS OF TREATMENT
11 CANCER ANOREXIA - MARKETED PRODUCTS
11.1 List of Cancer Anorexia Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 CANCER ANOREXIA - PIPELINE DRUGS
12.1 List of Cancer Anorexia Pipeline Drugs Across the Top 7 Markets
12.1 List of Amblyopia Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name – Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.
13. CANCER ANOREXIA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. CANCER ANOREXIA – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 CANCER ANOREXIA - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Cancer Anorexia - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Cancer Anorexia - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Cancer Anorexia - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Cancer Anorexia - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Cancer Anorexia - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Cancer Anorexia - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Cancer Anorexia - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Cancer Anorexia - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Cancer Anorexia - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Cancer Anorexia - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Cancer Anorexia - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Cancer Anorexia - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Cancer Anorexia - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Cancer Anorexia - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Cancer Anorexia - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Cancer Anorexia - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Cancer Anorexia - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Cancer Anorexia - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Cancer Anorexia - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Cancer Anorexia - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Cancer Anorexia - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Cancer Anorexia - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Cancer Anorexia - Access and Reimbursement Overview
16 CANCER ANOREXIA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 CANCER ANOREXIA MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 CANCER ANOREXIA MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 CANCER ANOREXIA - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 CANCER ANOREXIA - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 CANCER ANOREXIA - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 CANCER ANOREXIA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 CANCER ANOREXIA - UNMET NEEDS
10 CANCER ANOREXIA - KEY ENDPOINTS OF TREATMENT
11 CANCER ANOREXIA - MARKETED PRODUCTS
11.1 List of Cancer Anorexia Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 CANCER ANOREXIA - PIPELINE DRUGS
12.1 List of Cancer Anorexia Pipeline Drugs Across the Top 7 Markets
12.1 List of Amblyopia Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name – Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.
13. CANCER ANOREXIA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. CANCER ANOREXIA – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 CANCER ANOREXIA - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Cancer Anorexia - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Cancer Anorexia - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Cancer Anorexia - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Cancer Anorexia - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Cancer Anorexia - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Cancer Anorexia - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Cancer Anorexia - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Cancer Anorexia - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Cancer Anorexia - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Cancer Anorexia - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Cancer Anorexia - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Cancer Anorexia - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Cancer Anorexia - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Cancer Anorexia - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Cancer Anorexia - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Cancer Anorexia - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Cancer Anorexia - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Cancer Anorexia - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Cancer Anorexia - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Cancer Anorexia - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Cancer Anorexia - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Cancer Anorexia - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Cancer Anorexia - Access and Reimbursement Overview
16 CANCER ANOREXIA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 CANCER ANOREXIA MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 CANCER ANOREXIA MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
